MOLECULAR BIOLOGY, published by PLEIADES PUBLISHING INC, serves as a vital repository for the dissemination of innovative research within the fields of biochemistry, genetics, and molecular biology. With an ISSN of 0026-8933 and an E-ISSN of 1608-3245, this journal has been a mainstay in the scientific community since its inception, embracing its deep historical roots from 1971 to the present. Recognized for its qualitative contributions, MOLECULAR BIOLOGY is ranked in the Q3 quartile for Biophysics and Q4 for Structural Biology, placing it among select journals in its domain. Researchers and students alike benefit from its rigorous peer-reviewed articles, which focus on all aspects of molecular mechanisms and interactions. The journal's inclusion in prestigious databases underlines its commitment to academic excellence. The editorial board is dedicated to fostering the sharing of influential findings, making it an essential resource for advancing knowledge and innovation in molecular biology.

CHROMOSOMA is a prestigious journal dedicated to advancing the field of genetics, published by Springer in Germany. With an ISSN of 0009-5915 and an E-ISSN of 1432-0886, this journal has been a cornerstone in the publishing landscape since its inception in 1939, serving as a critical resource for researchers and professionals interested in the intricacies of chromosomal biology. Although it operates on a subscription basis, the journal's rigorous peer-review process ensures the dissemination of high-quality research findings. With a commendable Q2 ranking in both genetic and clinical genetics categories as of 2023, CHROMOSOMA aims to bridge theoretical concepts with practical applications in medicine and biology. Researchers will appreciate its relevance, as indicated by its Scopus ranks and integration of diverse topics ranging from molecular genetics to clinical implications. By fostering collaboration and knowledge-sharing among scholars, CHROMOSOMA continues to shape the future of genetic research.

Clinical Epigenetics is a pioneering open-access journal published by BMC, dedicated to advancing the field of epigenetics and its critical implications in clinical and translational research. Established in 2011, the journal has become an authoritative resource in the realms of developmental biology, genetics, and molecular biology, as evidenced by its impressive 2023 Scopus categorization as a Q1 journal in multiple domains including clinical genetics. With a robust impact factor and rankings that place it among the top quartiles in its fields—Rank #13 in Clinical Genetics and #14 in Developmental Biology—Clinical Epigenetics serves as an essential platform for researchers, professionals, and students alike, encouraging the dissemination of high-quality research findings. Operating from its United Kingdom headquarters, this journal not only contributes to scholarly dialogue across the globe but also supports unrestricted access to vital findings that push the boundaries of our understanding of epigenetic mechanisms and their clinical applications.

CHROMOSOME RESEARCH is a prestigious academic journal dedicated to advancing the field of genetics, published by SPRINGER. Operative since 1993, this journal is widely recognized for its contributions to the understanding of chromosomal dynamics, genetic interactions, and molecular biology, maintaining a significant impact factor that places it in the Q2 category within its field as of 2023. Despite being a non-open access publication, CHROMOSOME RESEARCH provides essential insights and peer-reviewed articles that are invaluable to researchers, professionals, and students alike, with continual publication through the convergence years stretching towards 2024. Furthermore, with a Scopus rank of #187 out of 347 in the Genetics category, it resides in the 46th percentile, epitomizing its relevance and scholarly rigor within the scientific community. For those engaged in the intricate study of genetics and chromosomal studies, CHROMOSOME RESEARCH remains a crucial resource for disseminating pivotal research findings and facilitating academic discourse.

RNA Biology is a premier journal published by Taylor & Francis Inc, focusing on the intricate and evolving field of RNA research. With an ISSN of 1547-6286 and E-ISSN of 1555-8584, this journal has established itself as an essential resource for professionals, researchers, and students engaged in both molecular and cell biology. Recognized in the 2023 quartile rankings, RNA Biology holds a distinguished Q1 category in Molecular Biology and a Q2 category in Cell Biology, indicative of its significant impact and reputation within the scientific community. The journal emphasizes the importance of RNA in various biological processes, highlighting both fundamental and applied aspects, which is crucial for advancing our understanding of gene expression and regulation. With a strong Scopus ranking, including Rank #105/410 in Molecular Biology and Rank #83/285 in Cell Biology, RNA Biology is not just a publication but a vital platform for sharing groundbreaking findings and insights into RNA research. With a convergence that spans from 2004 to 2024, the journal promises to continue its legacy of excellence in disseminating important discoveries in RNA science, contributing richly to ongoing scientific dialogue and innovation.

EMBO REPORTS, published by WILEY, is a premier journal in the fields of Biochemistry, Genetics, and Molecular Biology, recognized for its rigorous peer-review process and impactful scientific contributions. Established in the year 2000 in the United Kingdom, this journal has maintained a stellar reputation, reflected in its consistent positioning within the Q1 category across these disciplines as of 2023. EMBO REPORTS excels in disseminating high-quality and timely research that addresses fundamental questions and challenges in molecular biology and genetics, making it an invaluable resource for researchers, professionals, and students. With impressive Scopus rankings, including Genetics at the 32nd rank and a 90th percentile placement, it fosters an environment for scholarly exchange and advances in knowledge. While Open Access options are not available, the journal continues to enhance its impact through traditional subscription models, thereby maintaining wide visibility in the scientific community. Its ongoing evolution promises continued relevance and influence until at least 2024.

DEVELOPMENTAL CELL, published by CELL PRESS, stands as a premier journal in the fields of Biochemistry, Genetics and Molecular Biology, Cell Biology, and Developmental Biology. With a significant influence evidenced by its Q1 rankings across several categories in 2023 and a remarkable Scopus ranking placing it at the 98th percentile for Developmental Biology, this journal is pivotal for researchers and academics aiming to advance their understanding of cellular processes. Covering a broad range of topics from molecular mechanisms to cellular developmental pathways, DEVELOPMENTAL CELL publishes cutting-edge research articles that contribute to the dynamic landscape of cell biology and related disciplines. Although it does not currently offer open access, the journal is accessible through institutional subscriptions, reinforcing its commitment to disseminating high-quality scientific knowledge produced by leading experts in the field. Based in the United States, DEVELOPMENTAL CELL continues to push the boundaries of discovery and innovation in life sciences, making it an essential resource for professionals, researchers, and students alike in the quest for foundational biological insights.

GENES & DEVELOPMENT, published by COLD SPRING HARBOR LAB PRESS, stands as a premier journal in the fields of Developmental Biology and Genetics, boasting a remarkable impact factor that reflects its prestigious position in the academic community—ranking Q1 in both disciplines as of 2023. Since its inception in 1987, this journal has been at the forefront of disseminating cutting-edge research, effectively bridging the gap between laboratory breakthroughs and their applications in health and disease. Researchers and professionals rely on GENES & DEVELOPMENT for its rigorous peer-review process and its commitment to promoting innovative studies that unravel the complexities of gene functions and developmental processes. With Scopus rankings placing it in the top percentile among its peers, this journal serves as a vital resource for students and established scientists alike, aspiring to expand their knowledge and contribute to the ever-evolving landscape of genetic and developmental research.

CURRENT GENETICS is a prestigious journal published by SPRINGER, dedicated to advancing the field of genetics through the dissemination of high-quality research. With a notable impact factor and ranking in the Q2 category for both Genetics and Medicine (miscellaneous) as of 2023, it firmly establishes itself as a significant resource for the academic community. The journal’s comprehensive scope explores the latest findings in genetic research, along with accompanying interdisciplinary studies, providing a platform for researchers to share innovative ideas and methodologies. ISSN: 0172-8083, E-ISSN: 1432-0983, stands testament to its commitment to scholarly excellence. While Open Access options are not currently available, CURRENT GENETICS remains accessible to a broad audience, promoting a rich exchange of knowledge that supports the vast and evolving discipline of genetics. Since its inception in 1979 and through its converged years till 2024, this journal has played a crucial role in confronting scientific challenges and promoting advancements in genomic medicine and molecular biology. As such, it is an essential read for researchers, professionals, and students keen to remain at the forefront of genetic research.

Epigenetics, published by Taylor & Francis Inc, is a leading journal in the fields of Cancer Research, Medicine (miscellaneous), and Molecular Biology. With an ISSN of 1559-2294 and an E-ISSN of 1559-2308, this journal has been paving the way for groundbreaking research since its inception in 2006, and it continues to play a crucial role in advancing our understanding of epigenetic mechanisms and their implications in health and disease. The journal is highly regarded, ranking in the Q1 category for Medicine and Q2 for both Cancer Research and Molecular Biology according to the 2023 category quartiles. Researchers and professionals in the field will find invaluable insights and innovative studies within its pages, making it an essential resource for those engaged in cutting-edge research. Although the journal is not open access, it encourages a comprehensive understanding through high-quality peer-reviewed content. With its creative exploration of the epigenetic landscape, Epigenetics serves as a vital platform for the sharing of knowledge that could lead to breakthroughs in treatments and therapies.